Expert Opin Biol Ther. 2024 Aug 1. doi: 10.1080/14712598.2024.2388193. Online ahead of print.
ABSTRACT
OBJECTIVE: The aim of this study was to assess the efficacy and safety of etanercept (ETA) use in juvenile idiopathic arthritis (JIA).
METHODS: The 24-month data of patients with JIA on etanercept in a single center were evaluated retrospectively. Response to treatment was assessed according to 10-joint Juvenile Arthritis Disease Activity Score (JADAS10), and JIA-American College of Rheumatology (ACR) improvement criteria. Safety assessments were based on adverse event (AE) reports.
RESULTS: The study included 152 patients with JIA. The mean age at diagnosis of JIA was 8.5 ± 4.4 years, and treatment with ETA started at a mean age of 11.1 ± 4.4 years. The mean duration of ETA use was 16 ± 11.1 months. The mean JADAS10 score at baseline was 18.5 ± 5.9. By the third month, it had reduced to 8.6 ± 6.6 and by the sixth month to 5.7 ± 6. By the twelfth month, the JADAS10 score was 4.9 ± 6.7, and by the twenty-fourth month, it worsened to 7.3 ± 7.8. ACR50 response, was achieved in 79.6% of patients at three months, 67.1% at six months, 79.3% at twelfth months, 70.7% at twenty-fourth months. During ETA treatment, 10 patients required hospitalization for serious infections.
CONCLUSION: Etanercept is a safe and effective option for patients with JIA. However, variations in response between JIA subtypes highlight the need for individualized treatment strategies.
PMID:39088092 | DOI:10.1080/14712598.2024.2388193
